The acidity index: A simple approach to the measurement of gastric acidity

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 4, 2004, Pages 443-448

  Tutuian, R ^a   Castell, D O ^a   Xue, S ^b   Katz, P O ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b GRADUATE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDITY; ADULT; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CORRELATION ANALYSIS; EVALUATION; FEMALE; HUMAN; MALE; MATHEMATICAL COMPUTING; NORMAL HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES;

EID: 1542329563     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01853.x     Document Type: Article

References (14)

1. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500-11.
2. Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
3. Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 59-67.
4. Gardner JD, Rodriguez-Stanley S, Robinson M. Integrated acidity and the pathophysiology of gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 1363-70.
5. Williams MP, Sercombe J, Hamilton MT, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079-89.
6. Janczewska I, Sagar M, Sjostedt S, et al. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1239-43.
7. Gardner JD, Sloan S, Miner PB, Robinson M. Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor. Aliment Pharmacol Ther 2003; 17; 955-64.
8. Hirst BH. The gastric mucosal barrier. In: Forte JG, Schultz SG. eds. Handbook of Physiology. Gastrointestinal System. Salivary, Gastric, Pancreatic, and Hepatobiliary Secretion. Section 6, Vol. III, Chapter 15. Bethesda, MD: American Physiological Society, 2001: 279-308.
9. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 763-7.
10. Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12: 1235-10.
11. Huang JQ, Hunt RH. pH, healing rate and symptom relief in acid-related diseases. Yale J Biol Med 1996; 69: 159-74.
12. Ladas SD, Tassios PS, Raptis SA. Selection of patients for successful maintenance treatment of esophagitis with low-dose omeprazole: use of 24-hour gastric pH monitoring. Am J Gastroenterol 2000; 95: 374-80.
13. Rebecchi FFI, Giaccone C, Morino M. Improving the analysis of esophageal acid exposure by a new parameter: area under H+. Am J Gastroenterol 2002; 97: 568-74.
14. Pursnani KG, Mohiuddin MA, Geisinger KR, et al. Experimental study of acid burden and acute oesophagitis. Br J Surg 1998; 85: 677-80.